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Hypertrophic Cardiomyopathy Without Hypertrophy
An Emerging Pre-Clinical Subgroup Composed of Genetically Affected
Family Members*
Barry J. Maron, MD, FACC, Carolyn Y. Ho, MD
Minneapolis, Minnesota; and Boston, MassachusettsHypertrophic cardiomyopathy (HCM) is character-
ized by an exceedingly broad spectrum of pheno-
typic expression (1–3). This disease, initially re-
garded as typically associated with diffuse and
particularly substantial left ventricular (LV) wall
thickening and mass, has now been shown to
include morphologic forms demonstrating a wide
range in the magnitude of LV hypertrophy (3).
Indeed, mild and segmental wall thickening consti-
tutes an important proportion of the HCM mor-
phologic spectrum, as underscored by a recent
cardiovascular magnetic resonance imaging study
that showed that fully 20% of patients with a
clinically expressed HCM phenotype (namely, in-
creased LV wall thickness) paradoxically showed
normal overall LV mass (4).
See page 58
Furthermore, an intriguing and evolving subset
comprising asymptomatic children and adult family
members, who inherit a disease-causing mutation
encoding proteins of the cardiac sarcomere (but
appear clinically unaffected with normal LV wall
thickness and mass), is now being identified with
greater frequency owing to the expanding availabil-
ity of diagnostic genetic testing for HCM. By way
of definition, such genotype-positive–phenotype-
negative family members are encountered within
either of 2 clinical scenarios. Most commonly, of
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Hypertrophic Cardiomyopathy Center, Minneapolis Heart
Institute Foundation, Minneapolis, Minnesota, and Cardiovascular Divi-
sion, Brigham and Women’s Hospital, Harvard Medical School, Boston,
Massachusetts.these are pre-adolescents before the abrupt onset of
LV wall thickening, which usually occurs at ages 13
to 17 years, associated with accelerated growth and
maturation (5). Less frequently, a few other HCM
family members have been documented with de-
layed, age-dependent phenotypic penetrance in
which evolution to LV hypertrophy occurs much
later into midlife and beyond (adult-onset hyper-
trophy) (6,7).
However, there are many unresolved issues con-
cerning the pathophysiology and natural history of
patients with pre-clinical HCM. Do these patients
with only sarcomere mutations in fact harbor a
pathologic condition (namely, HCM), and what are
the potential complications (if any) or clinical
course of this subset? Is the LV structurally and
functionally abnormal (i.e., “cardiomyopathic”)
while not obviously hypertrophied? Are these ge-
netically affected individuals all predestined to de-
velop the HCM phenotype with LV wall thicken-
ing, or can LV hypertrophy remain absent
throughout a life-time in genetically affected
persons?
It is the latter question concerning the morpho-
logic and functional condition of the myocardium
in apparently healthy at-risk family members that
has been addressed by several lines of investigation.
A number of years ago, 12-lead electrocardiogram
patterns were noted to be distinctly abnormal before
the appearance of LV hypertrophy on echocardio-
gram in HCM family members, with the magni-
tude of precordial and standard lead voltages pre-
dictive for the degree of future LV hypertrophy (8).
The underlying cellular abnormalities responsible
for such early alterations in electrocardiographic
pattern remain unresolved, but could be related to
the alternations in diastolic filling discussed in the
following text.
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66Genetically modified animal models of HCM
heterozygous knock-in mice and transgenic rabbits
ith the myosin heavy chain missense mutation,
rg403Gln) have provided the initial insight that
bnormalities of diastolic function could precede
he development of LV hypertrophy (as well as
yocyte hypertrophy and disarray, or myocardial
eplacement fibrosis) (9 –12). Subsequently, 3
roups of investigators have used tissue Doppler
maging (TDI) and 2-dimensional echocardiogra-
hy to study genetically affected but asymptomatic
amily members without LV hypertrophy, demon-
trating that altered functional parameters of LV
elaxation and diastolic function can be identified in
his pre-hypertrophic phase.
In this regard, Ho et al. (13) studied 18
utation-positive–phenotype-negative relatives
ith mutations in the beta-myosin heavy chain
ene and found early mitral annular diastolic (Ea)
elocity to be significantly lower than in controls,
nd indicative of impaired relaxation. Nevertheless,
a velocity was not significantly sensitive as a sole
iagnostic criterion to discriminate family members
ith normal LV wall thickness who carried sar-
omere mutations from those who did not. How-
ver, when combined with hyperdynamic LV func-
ion (ejection fraction 68%), low Ea velocity was
ighly predictive of a genotype in those young
ersons without overt manifestations of HCM.
omewhat in contrast, Nagueh et al. (14) studied 13
ene-positive–phenotype-negative relatives with
eta-myosin heavy chain, myosin-binding protein
(MBPC3), and troponin T mutations and re-
orted Ea velocities to be 40% lower than in
ormal control subjects, and itself highly specific for
re-clinical HCM. Finally, Cardim et al. (15)
eported a family with 5 pre-clinical HCM mem-
ers in whom markedly reduced Ea velocities were
dentified.
The study of Michels et al. (16) from the Neth-
rlands in this issue of iJACC employs a design
imilar to that in prior reports to study 27 gene-
ositive–phenotype-negative relatives who carry 1
f 3 different Dutch MBPC3 founder mutations
17), each predicted to cause truncation of the pro-
ein due to small insertion/deletions (c.2373dupG
nd c.2864-2865delCT) or premature termination
Arg943X). These data contribute to the available
xperience in characterizing diastolic abnormalities
n genetically affected HCM family members with-
ut LV hypertrophy. However, in contrast to prior
tudies, neither global or regional Ea and mitral
nnular systolic (Sa) velocities in the gene-positive– Mhenotype-negative relatives differed from controls;
hese parameters were, nevertheless, reduced com-
ared with those of family members expressing the
vert HCM phenotype with LV wall thickening.
he sole metric of abnormal diastolic function in
he study of Michels et al. (16) was increased late
iastolic (Aa) velocity in the pre-clinical subset
elative to controls.
It is perhaps surprising that the authors did not
nd a significant reduction in Ea, as has been
onsistently identified in the other studies (includ-
ng that of Nagueh et al. [14]) in which more than
ne-half of the gene-positive–phenotype-negative
ohort bear the same MYBPC3 mutation as 30% of
he subjects in the present report (c.2373dupG, also
nown as InsG791). This discrepancy may be
elated to the unusually low Ea velocities evident in
he control population used. Nevertheless, Michels
t al. (16) concluded that while TDI velocities were
ot sufficiently sensitive to reliably predict genotype
tatus in individual family members, their data are
evertheless consistent with the principle that dia-
tolic function is often altered in pre-clinical HCM
efore development of LV wall thickening. There-
ore, it is important to underscore that TDI abnor-
alities are not ideal diagnostic markers in this
symptomatic pre-clinical subset and cannot substi-
ute for genetic testing to achieve definitive identi-
cation of genetically affected HCM family mem-
ers. Nevertheless, TDI has proved useful in
haracterizing early functional LV abnormalities
nd providing potentially important insights into
he disease pathogenesis of HCM.
The mechanisms underlying diastolic dysfunc-
ion in pre-clinical HCM are not completely un-
erstood, although data from animal models have
ncriminated altered cross-bridge kinetics, where
he presence of a sarcomere mutation slows the rate
f dissociation of actin and myosin (10,11). Fur-
hermore, altered intracellular calcium handling
ith a decreased rate of calcium uptake into sarco-
lasmic reticulum may also contribute to the im-
aired relaxation (18,19).
Major questions remain concerning the manage-
ent of pre-clinical HCM family members, and are
ecoming increasingly relevant with the greater
enetration of commercially available genetic test-
ng for HCM. At present, treatment strategies
ncluding drugs and primary prevention implant-
ble defibrillators are generally not recommended
or such genetically affected persons without LV
ypertrophy. For example, our HCM center in
inneapolis has prophylactically implanted defi-
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67rillators in only 2 adults in this subgroup, both
ith a strong family history of HCM-related sud-
en cardiac death due to HCM (and to date neither
as experienced an appropriate device intervention).
However, a clinical dilemma arising with increasing
requency involves young genotype-positive–
henotype-negative persons who are engaged in com-
etitive athletic programs. The 36th Bethesda Con-
erence recommendations (20) are relatively liberal
egarding such athletes with sarcomere mutations,
llowing full participation in the absence of the HCM
henotype (i.e., LV hypertrophy). On the other hand,
he European Society of Cardiology recommenda-
ions (21) are more restrictive in this regard, and have
isqualified athletes from competition based solely on
he presence of a mutation. Such difficult clinical
ecisions concerning eligibility for competitive sports
re further compounded when HCM-related sudden
eath is part of the family history.
In conclusion, there are accumulating data
btained largely with TDI in asymptomatic
CM family members (who have inherited the
enetic substrate) that underscore the principleof left ventricular hypertrophy in chil- 101:1775–83.e present before the development of hypertro-
hy. Indeed, subtle but demonstrable cardiomyo-
athic changes usually consisting of diastolic
ysfunction can be a primary component of
re-clinical HCM. Furthermore, these abnor-
alities in diastolic function appear to be early
nd fundamental manifestations of sarcomere
utations. However, the clinical significance of
uch TDI imaging findings remains unre-
olved—in other words, whether evidence of
iastolic dysfunction represents a marker for the
uture evolution of LV hypertrophy, cardiac
ymptoms, or major cardiac events, and whether
t should be the basis for restricting a physically
ctive life-style. As is often the case in HCM,
nswers to these important questions regarding
his novel patient subgroup will require longitu-
inal clinical studies carried out over substantial
eriods of time.
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